The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) hit a new 52-week low and has $11.87 target or 14.00% below today’s $13.80 share price. The 5 months bearish chart indicates high risk for the $386.23 million company. The 1-year low was reported on Oct, 28 by Barchart.com. If the $11.87 price target is reached, the company will be worth $54.07 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 63,637 shares traded hands. Atara Biotherapeutics Inc (NASDAQ:ATRA) has declined 20.09% since March 28, 2016 and is downtrending. It has underperformed by 24.81% the S&P500.
Analysts await Atara Biotherapeutics Inc (NASDAQ:ATRA) to report earnings on November, 3. They expect $-0.69 earnings per share, down 60.47% or $0.26 from last year’s $-0.43 per share. After $-0.66 actual earnings per share reported by Atara Biotherapeutics Inc for the previous quarter, Wall Street now forecasts 4.55% negative EPS growth.
Atara Biotherapeutics Inc (NASDAQ:ATRA) Ratings Coverage
Out of 6 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 4 rate it a “Buy”, 2 “Sell”, while 0 “Hold”. This means 67% are positive. Atara Biotherapeutics has been the topic of 13 analyst reports since September 9, 2015 according to StockzIntelligence Inc. The company was initiated on Friday, September 25 by JMP Securities. The firm has “Market Outperform” rating given on Tuesday, December 15 by JMP Securities. The firm earned “Buy” rating on Monday, October 24 by Jefferies. The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) earned “Sell” rating by Citigroup on Tuesday, December 15. The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) has “Sell” rating given on Monday, August 22 by Citigroup. Citigroup maintained Atara Biotherapeutics Inc (NASDAQ:ATRA) on Friday, August 19 with “Sell” rating. Goldman Sachs downgraded the stock to “Sell” rating in Thursday, September 15 report. Goldman Sachs initiated the stock with “Neutral” rating in Wednesday, November 18 report. JMP Securities maintained the shares of ATRA in a report on Wednesday, March 9 with “Market Outperform” rating. As per Wednesday, September 9, the company rating was initiated by Canaccord Genuity.
According to Zacks Investment Research, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California.”
Insitutional Activity: The institutional sentiment increased to 3.36 in Q2 2016. Its up 2.20, from 1.16 in 2016Q1. The ratio increased, as 6 funds sold all Atara Biotherapeutics Inc shares owned while 8 reduced positions. 7 funds bought stakes while 40 increased positions. They now own 43.46 million shares or 112.65% more from 20.44 million shares in 2016Q1.
Vident Inv Advisory Ltd Liability Co, a Georgia-based fund reported 32,879 shares. The New York-based Slate Path Cap Lp has invested 0.74% in Atara Biotherapeutics Inc (NASDAQ:ATRA). Savings Bank Of America Corp De owns 75,926 shares or 0% of their US portfolio. Geode Capital Management Ltd Liability Company, a Massachusetts-based fund reported 137,725 shares. California State Teachers Retirement Sys holds 0% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 48,704 shares. Blackrock has invested 0% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA). Ubs Asset Mngmt Americas Inc accumulated 1.15M shares or 0.03% of the stock. Metropolitan Life Ins Ny reported 17,716 shares or 0% of all its holdings. Barclays Public Ltd last reported 4,803 shares in the company. Teachers Advsrs, a New York-based fund reported 102,251 shares. Moreover, Blackrock Fund Advsrs has 0% invested in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 913,922 shares. Ladenburg Thalmann Fin Svcs Inc holds 0% or 22 shares in its portfolio. Citigroup holds 0% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 5,996 shares. Bnp Paribas Arbitrage accumulated 0% or 937 shares. Perceptive Ltd Limited Liability Company has 2,500 shares for 0% of their US portfolio.
Insider Transactions: Since May 16, 2016, the stock had 0 buys, and 16 selling transactions for $2.00 million net activity. Ciechanover Isaac E. sold $246,372 worth of stock. $120,040 worth of Atara Biotherapeutics Inc (NASDAQ:ATRA) was sold by Soffer Gad. On Tuesday, October 11 the insider MCGRATH JOHN sold $87,325. On Monday, August 15 Haqq Christopher sold $30,041 worth of the stock or 1,346 shares. Clark Mitchall G. sold 4,153 shares worth $62,918. Shares for $18,897 were sold by Gallagher Carol Giltner.
More news for Atara Biotherapeutics Inc (NASDAQ:ATRA) were recently published by: Marketwatch.com, which released: “Atara Biotherapeutics stock price target cut to $16 from $23 at Goldman Sachs” on October 17, 2014. Fool.com‘s article titled: “Why Atara Biotherapeutics Inc. Shares Are Getting Mauled Today” and published on December 14, 2015 is yet another important article.
ATRA Company Profile
Atara Biotherapeutics, Inc., incorporated on August 22, 2012, is a clinical-stage biopharmaceutical company. The Firm is focused on developing therapies for patients with severe and life-threatening diseases. The Company’s segment is the business of developing and commercializing therapeutics. The Firm has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. The Company’s T-cell product candidates arise from a platform technology designed to produce off-the-shelf, partially human leukocyte antigen (HLA) matched cellular therapeutics utilizing cytotoxic T lymphocytes (CTLs). The Company’s T-cell product candidates target viral or cancer-specific antigens, and are designed to harness the body’s immune system to counteract specific viral infections and cancers. The Company’s T-cell product candidates include Epstein Barr Virus (EBV)-CTL, which is in Phase II clinical trials for malignancies associated with EBV, including EBV-associated post-transplant lymphoproliferative disorders (EBV-PTLD); cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1 and is in Phase I clinical trials.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.